In the Drug Profile by LF Meneghini and B Miranda-Palma, ‘Insulin degludec: a novel ultra-long-acting basal insulin for use in Type 1 and 2 diabetes’, published in the January 2012 issue of Expert Review of Endocrinology and Metabolism (Expert Rev. Endocrinol. Metab. 7[1], 9–14 [2012]), on page 10, the following sentence appeared as:
“Steady-state area under the curve for GIR (AUCGIR) was four-times lower for insulin degludec [7].”
The sentence should have read:
“Steady-state area under the curve for GIR (AUCGIR) was four-times less variable for insulin degludec [7].”
The authors and editors of Expert Review of Endocrinology and Metabolism would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.